SCHEMBL15420156

SCHEMBL15420156

Cc1nc(-c2ccc(OC[C@H]3OCCC[C@@H]3NS(=O)(=O)C3CC3)cc2)cs1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.49
MAPK1 P28482 2/20 0.49
RAB9A P51151 7/20 0.45
ALDH1A1 P00352 7/20 0.45
NPC1 O15118 5/20 0.45
TSHR P16473 4/20 0.45
HPGD P15428 2/20 0.45
HSD17B10 Q99714 1/20 0.45
SMN1; SMN2 Q16637 4/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
NPSR1 Q6W5P4 3/20 0.40
RXFP1 Q9HBX9 1/20 0.40
ATP4A P20648 2/20 0.39
ATP4B P51164 2/20 0.39
HTT P42858 2/20 0.39
POLB P06746 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.38
USP2 O75604 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15420525 0.91 LMNA (0.51) LMNAMAPK1RAB9AALDH1A1NPC1
SCHEMBL15420505 0.90 LMNA (0.52) LMNAMAPK1RAB9AALDH1A1NPC1
SCHEMBL15420297 0.85 TP53 (0.43) LMNAMAPK1NPC1MEN1KMT2A
SCHEMBL15420636 0.83 CXCR1 (0.36) LMNAMAPK1RAB9AALDH1A1NPC1
SCHEMBL15420919 0.81 NPC1 (0.43) RAB9AALDH1A1NPC1HPGDSMN1; SMN2
SCHEMBL21795673 0.80 RAB9A (0.37) LMNAMAPK1RAB9AALDH1A1NPC1
SCHEMBL15420302 0.80 SCN9A (0.40) LMNAMAPK1RAB9AALDH1A1NPC1
SCHEMBL15420021 0.80 RAB9A (0.37) LMNAMAPK1RAB9AALDH1A1NPC1
SCHEMBL15420860 0.80 KDM4E (0.41) LMNAMAPK1ALDH1A1HPGDHTT
SCHEMBL15420030 0.78 SCN9A (0.35) LMNARAB9AALDH1A1NPC1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2694472-B1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2020-03-11 EP disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF GRIN2A, GRIN2B, SLC1A2 LMNA 4794/4885MAPK1 1793/4885RAB9A 3305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.